Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain

(2013) F. Graus et al.   NEURO-ONCOLOGY

Epidemiology of glial and non-glial brain tumours in Europe

(2012) Emanuele Crocetti et al.   EUROPEAN JOURNAL OF CANCER

Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme

(2012) Gloria B. Roldán Urgoiti et al.   JOURNAL OF NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

Intérêt d’un traitement d’entretien prolongé par témozolomide dans la prise en charge des patients atteints d’un glioblastome

(2011) N. Malkoun et al.   Cancer Radiotherapie

Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression

(2011) Nadia Malkoun et al.   JOURNAL OF NEURO-ONCOLOGY

Controversies in the Adjuvant Therapy of High-Grade Gliomas

(2011) M. Holdhoff et al.   ONCOLOGIST

High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) R. Stupp et al.   ANNALS OF ONCOLOGY

Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

(2010) S. A. Grossman et al.   CLINICAL CANCER RESEARCH

Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005

(2010) Rafael Fuentes-Raspall et al.   JOURNAL OF NEURO-ONCOLOGY

Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004

(2010) L. Bauchet et al.   NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Adjuvant temozolomide: how long and how much?

(2008) Enrico Franceschi et al.   Expert Review of Anticancer Therapy

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology

(2008) Alba A. Brandes et al.   NEURO-ONCOLOGY